LLY•benzinga•
Mounjaro Maker Eli Lilly Clocks 45% Jump In Q1 Revenue, Cuts 2025 Profit Outlook But Not Due To Tariffs
Summary
Eli Lilly cut its 2025 profit outlook after strong Q1 sales from Mounjaro and Zepbound and a $1.57 billion charge tied to a cancer drug acquisition.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 1, 2025 by benzinga